- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Medicare Advantage Continues to Offer More Choices, Lower Premiums to America’s Seniors
The average Medicare Advantage monthly premium in 2021 will be $21, a 11% decrease from 2020 premiums.
WASHINGTON – CMS announced yesterday its estimated 2021 monthly Medicare Advantage (MA) premiums. According to the agency, the average MA monthly premium in 2021 will be $21, a 11% decrease from 2020 premiums and a 34% reduction from 2017 premiums. In addition, CMS announced that the average number of plan choices per county will increase from 39 plans in 2020 to 47 plans in 2021. Overall, nearly 5000 MA plans will be available across the country in 2021.
CMS also announced that MA enrollment is projected to reach approximately 26.9 million enrollees next year, up from 24.4 million enrollees in 2020. That means that MA will cover 42% of all Medicare beneficiaries.
“America’s seniors are increasingly choosing Medicare Advantage because it delivers better services, better access to care, and better value,” said Matt Eyles, president and CEO of America’s Health Insurance Plans. “And polls show that people in Medicare Advantage are overwhelmingly satisfied with their plan. That’s why we’ll continue to fight for a strong and stable program—both now and in the future.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
